Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer

24 May 2024

Abstract excerpt

BACKGROUND: AT-rich interaction domain 1A (ARID1A) has been proposed as a new biomarker for predicting response to immune checkpoint inhibitors (ICIs). The predictive value of ARID1A for predicting ICI effectiveness has not been reported for endometrial cancer. Therefore, we investigated whether ARID1A negativity predicts ICI effectiveness for endometrial cancer treatment. METHODS: We evaluated ARID1A expression,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Endometrial and Cervical Cancer Treatments
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38893118
DOI: 10.3390/cancers16111999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial CancerPMID 38893118Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinomaSemantic proximity Read ↗

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaSemantic proximity Read ↗

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

Prognostic role of transcription factor ARID1A in patients with endometrial cancer of no specific molecular profile (NSMP) subtype.Semantic proximity Read ↗

Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers‡.Semantic proximity Read ↗

ARID1A: gene, protein, and function in endometrial cancer.Semantic proximity Read ↗

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitorsSemantic proximity Read ↗

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapySemantic proximity Read ↗

Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.Semantic proximity Read ↗

ARID1A in Gynecologic Precancers and Cancers.Semantic proximity Read ↗

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.